Stoke Therapeutics, Inc. (STOK) Misses Q2 EPS by 6c

Stoke Therapeutics, Inc. (NASDAQ: STOK) reported Q2 EPS of ($0.69), $0.06 worse than the analyst estimate of ($0.63).

For earnings history and earnings-related data on Stoke Therapeutics, Inc. (STOK) click here.

You May Also Be Interested In

• Are we witnessing a fundamental or speculative rally in the S&P 500?
• Palo Alto Networks stock dips despite quarterly beat, raised profit outlook
• Petco Health and Wellness (WOOF) Misses Q1 EPS by 6c